an independent editorial reading

What this site is

Telehealth GLOW is an independent editorial project that publishes summaries of the peer-reviewed research literature on the GLOW research-peptide blend — the three-component co-formulation of GHK-Cu, BPC-157, and TB-500 marketed under that community-derived name. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. We do not provide telehealth services, prescriptions, or referrals to any provider. Our work is editorial commentary on publicly available science.

The word 'telehealth' in our domain name is editorial framing — a position the publisher occupies relative to a fast-moving and heavily regulated prescribing landscape, not a claim about services this site offers. The most-searched intent around 'telehealth GLOW' is some version of 'can I get this prescribed virtually,' and the most-useful editorial response is a careful, sourced reading of the research and the regulatory posture that constrains the answer. That is what we publish.

What we explicitly are not

We are not a telehealth provider. We are not a clinic. We do not run a virtual prescribing service, an asynchronous-messaging consult model, or a video-visit platform. We do not have doctors on staff, pharmacists on staff, or a clinical team. We do not have a physical address that dispenses anything. We do not have a referral network of prescribers. If you arrived here looking for a telehealth visit, this is the wrong site — and the regulatory posture around the components of GLOW (see the FDA Category 2 status of BPC-157, in effect since September 2023) constrains that landscape regardless of where you look ^[16].

We are also not a vendor. We do not sell GHK-Cu, BPC-157, TB-500, the GLOW blend, or anything else. We are not affiliated with any vendor, compounding pharmacy, research-chemical distributor, or telehealth platform. The footer disclaimer on every page makes this explicit, and it is meant literally.

Editorial methodology

Every quantitative claim on this site cites a specific peer-reviewed paper. Dose values, study sizes, percentage effects, half-life numbers — all are traceable through the inline [N] markers to the references index. We work from PubMed, PubMed Central, ClinicalTrials.gov, journal publisher pages, and FDA-published documents. Where the literature is sparse or absent — as it is for the full GLOW combination — we say so plainly.

We do not use anonymized expert opinion. We do not paraphrase Reddit or forum content. We do not invent representative case histories. If a claim is not in the indexed literature, we either do not write it or we mark its absence as the editorial point ('no peer-reviewed combination study exists').

We write in the third person, attribute every dose and effect to a specific study, and use the phrase 'studied at X in [species]' framing throughout. We do not recommend doses. We do not recommend administration routes. We do not endorse compounding pharmacies, vendors, or telehealth providers.

Why the visual design looks the way it does

The chromatic-aberration / RGB-split design language on this site is a deliberate editorial argument made through visual vocabulary. GLOW is three separately-studied compounds being marketed as one stack. The three pure-RGB primaries used as a structural legend — red for GHK-Cu, green for BPC-157, blue for TB-500 — literalize that decomposition on every page. Display headings carry a chromatic-split shadow that almost-but-does-not-quite register, just as the three peptides almost-but-do-not-quite combine into a single research record.

Body text and small UI text remain clean off-white on near-black with AAA contrast at 17px — the chromatic-split treatment is strictly for display headings and decorative numerals, gated behind prefers-reduced-motion for users who request reduced motion. The aesthetic carries the argument; the reading layer stays calm.